创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

李琬琼, 高艳锋. 抗肿瘤多肽药物研究进展[J]. 药学进展, 2019, 43(10): 759-766.
引用本文: 李琬琼, 高艳锋. 抗肿瘤多肽药物研究进展[J]. 药学进展, 2019, 43(10): 759-766.
LI Wanqiong, GAO Yanfeng. Research Progress on Anti-tumor Peptide Drugs[J]. Progress in Pharmaceutical Sciences, 2019, 43(10): 759-766.
Citation: LI Wanqiong, GAO Yanfeng. Research Progress on Anti-tumor Peptide Drugs[J]. Progress in Pharmaceutical Sciences, 2019, 43(10): 759-766.

抗肿瘤多肽药物研究进展

Research Progress on Anti-tumor Peptide Drugs

  • 摘要: 恶性肿瘤是严重威胁人类健康的重大疾病,随着人们对肿瘤发生机制和免疫微环境认识的深入,在传统手术、放疗和化疗的基础上寻求新的诊断和治疗手段是当前研究的热点。多肽药物相较于小分子化学药物和单抗药物,具有独特的性质,可以作为激素和抑制剂,也可以作为多肽疫苗激活抗肿瘤免疫反应,且有望成为很好的分子诊断工具。综述抗肿瘤多肽药物的作用机制、结构优化、靶向多肽和自组装,以及未来的发展趋势等方面的研究进展。

     

    Abstract: Cancer is a big threat to human health. Along with the understanding of the mechanisms of cancer progression and microenvironment, it has become very urgent to develop novel diagnostic and therapeutic strategies beyond conventional surgery, radiotherapy and chemotherapy. Compared with small molecule chemical and monoclonal antibody drugs, peptides are quite unique to act not only as hormones and inhibitors, but also as peptide vaccines to activate antitumor immune response. They could also be developed as molecular diagnostic tools. This review focuses on the recent progress of the mechanism of anti-tumor peptide, peptide optimization, targeting peptides and self-assembly, and future directions of anti-tumor peptides.

     

/

返回文章
返回